{"nctId":"NCT01290731","briefTitle":"A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","startDateStruct":{"date":"2011-01"},"conditions":["Hepatitis C, Chronic"],"count":49,"armGroups":[{"label":"TMC435 100 mg 12 Wks + PR24/48","type":"EXPERIMENTAL","interventionNames":["Drug: TMC435","Drug: Pegylated interferon (pegIFN alpha-2a)","Drug: Ribavirin (RBV)"]}],"interventions":[{"name":"TMC435","otherNames":[]},{"name":"Pegylated interferon (pegIFN alpha-2a)","otherNames":["PEGASYS"]},{"name":"Ribavirin (RBV)","otherNames":["COPEGUS"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have chronic genotype 1 HCV with HCV RNA level \\>= 5.0 log10 IU/mL\n* Participant relapsed after previous IFN-based therapy\n* Participant must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication.\n\nExclusion Criteria:\n\n* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)\n* Diagnosed with hepatic cirrhosis or hepatic failure\n* A medical condition which is a contraindication to pegIFN or ribavirin therapy\n* History of, or any current medical condition, which could impact the safety of the patient in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","description":"The table below shows the percentage of participants with an SVR12 defined as participants with undetectable plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at the end of treatment (Week 24 or 48) who also had undetectable plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) 12 weeks after the last dose of treatment (Week 36 or 60).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)","description":"The table below shows the percentage of participants with a SVR24 defined as participants with undetectable plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at the end of treatment (Week 24 or 48) and at 24 weeks after the last dose of treatment (Week 48 or 72).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up","description":"The table below shows the percentage of participants with greater than or equal to 2 log10 IU/mL drop from baseline in plasma HCV RNA at each time point during treatment, at the end of treatment (Week 24 or 48), and post-treatment follow-up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)","description":"The table below shows the percentage of participants with undetectable HCV RNA (defined as less than 1.2 log10 IU/mL during treatment at Weeks 4, 12, 24, 36, 48, 60, 72, and at EOT \\[Week 24 or 48\\]).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Viral Breakthrough","description":"Viral breakthrough was defined as a confirmed increase of greater than 1 log10 IU/mL in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels from the lowest level reached or a confirmed value of plasma HCV RNA of \\> 2.0 log10 IU/mL in particpants whose plasma HCV RNA level had previously been below 1.2 log10 IU/mL detectable or undetectable during the treatment period. The table below shows that no viral breakthrough was noted in any participants during the treatment period of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Demonstrating Viral Relapse","description":"The table below shows the number of participants who demonstrated viral relapse, defined as undetectable Hepatitis C Virus Ribonucleic Acid (HCV RNA) at end of treatment (EOT) and detectable HCV RNA during follow-up or detectable HCV RNA at the time points of sustained virologic response (SVR) assessment . The incidence of viral relapse was calculated for participants with undetectable HCV RNA levels at EOT and with at least one follow-up HCV RNA measurement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations of TMC435","description":"The table below shows median (range) TMC435 predose plasma concentration (C0h) values and the TMC435 maximum plasma concentration (Cmax) values for all participants who received TMC435 for up to 12 weeks. \"Overall\" is the median exposure estimate using all available data for each participant in the study.Sparse blood samples were collected during the study (blood sampling times were 3 and 5 hours post- dose at Week 2 and Week 8 and pre-dose and 2 hours post-dose at Week 4 and Week 12).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1822","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3440","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435","description":"The table below shows the median (range) AUC24h values for TMC435 for all participants who received TMC435 for up to 12 weeks. \"Overall\" is the median exposure estimate using all available data for each participant in the study. Sparse blood samples were collected during the study (blood sampling times were 3 and 5 hours post- dose at Week 2 and Week 8 and pre-dose and 2 hours post-dose at Week 4 and Week 12).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63261","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)","description":"The table below shows the number of participants with abnormal ALT levels at baseline (Day 1) who achieved normalization of ALT levels (defined as an ALT value less than or equal to the Upper Limit of Normality \\[ie, 40 IU/mL\\] at EOT). At baseline, 15/49 participants had abnormal ALT levels.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":49},"commonTop":["Pyrexia","Neutrophil count decreased","White blood cell count decreased","Headache","Malaise"]}}}